Will proteomics design next-generation management of cardiovascular diseases?  by Fontana, P. & Reny, J.-L.
Translational Proteomics 7 (2015) 1–2Editorial
Will proteomics design next-generation management of cardiovascular
diseases?
Contents lists available at ScienceDirect
Translational Proteomics
journal homepage: http : / /www.else vie r .com/ locate / t rprotCardiovascular disorders are lead by atherothrombosis, a
complex and multifactorial disease. Atherothrombosis involves
several actors such as smooth muscle cells, endothelium, platelets,
immune system and inﬂammation [1]. Over the last decades, risk
factors such as smoking, diabetes, dyslipidemia and hypertension
have been identiﬁed but very few biomarkers speciﬁcally related to
the disease are routinely used. Risk factors have been computed
into risk scores to classify patients but their ability to predict
recurrence of ischemic events is limited. In addition, the
pharmaceutical industry deployed tremendous efforts in the
recent years to develop new compounds to decrease the
cardiovascular-related mortality but it seems that we have now
reached a plateau with little incremental value of new drugs on
cardiovascular outcomes.
High throughput technologies such as proteomics are now
opening new avenues for the dissection of vascular disorders and
are promising for the discovery of new biomarkers and targets that
may signiﬁcantly inﬂuence the management of vascular disorders.
However, this approach is associated with several caveats
including sample preparation, study design, analytical issues
and data management. In the present issue of Translational
Proteomics, four papers review the contribution of proteomics to
various cardiovascular diseases in a very brilliant manner. The
paper by de la Cuesta et al. [2] thus describes some very practical
aspects of proteomics in the ﬁeld of atherothrombosis, a major
worldwide cause of morbidity and mortality. They address the
functional validation of protein target as well the risks and
limitations of proteomic studies for a more critical appraisal of this
research literature. Velez and Garcia [3] show in their review how a
proteomic approach is particularly relevant to the study of
important nucleus-free cell fragments, namely platelets. Platelet
are widely involved in thrombosis and bleeding through various
disorders, some of which still needs to be uncovered and looking at
the end product of gene is naturally attractive in cells lacking DNA
or for which relying on the sole study of remnant RNAs may be
insufﬁcient. Lipoproteins are also major players in the pathogene-
sis and the complications of cardiovascular diseases. von Zychlinski
and Kleffmann address in their paper [4] the potential of
lipoprotein proteomics in cardiovascular diseases fostering on
the identiﬁcation on new biomarkers for cardiovascular risk
assessment though the review of studies in the ﬁeld and ahttp://dx.doi.org/10.1016/j.trprot.2015.01.002
2212-9634/ã 2015 The Authors. Published by Elsevier B.V. This is an open access article uncomprehensible description of new techniques and future
perspectives. The importance of proteomic studies for the
identiﬁcation and validation of biomarkers in cardiovascular
diseases is also covered in a very insightful manner by Beck
et al. [5]. They provide in their review a description of the key
challenges and considerations, including strategies, recent discov-
eries and clinical applications in cardiovascular proteomics and the
potential of using combinatorial panels of markers. Altogether
these reviews will provide you with up-to-date information with
very nice and informative ﬁgures and charts, all by experts in the
ﬁeld who aimed to give a balanced and critical description of
proteomics in cardiovascular medicine.
High throughput technologies such as quantitative proteomics
and transcriptomics yield large data sets that need cutting-edge
bioinformatics tools to be properly mined. This is another area of
intense research that should parallel proteomics and other ‘omics
development. In that regard, network biology permitting the
integration of different ‘omic data sets and the identiﬁcation of
mutual interactions between gene products and/or molecules is
particularly promising [6,7]. Finally, in addition to the functional
validation of protein targets, the replication in independent
cohorts of patients will remain an important validation step that
will raise the possibility of altering management of cardiovascular
diseases. Therefore, the collaboration of proteomics experts
together with clinicians is essential to ensure translation of
forthcoming discoveries into clinical practice.
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